<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="editorial">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">sGRcwyDrZy6Y6skNLJ77PYC</article-id>
      <article-id pub-id-type="other">00026</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001100026</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500126</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010001100026</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Ponto de Vista</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cardiologista: um Prometeu acorrentado</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Robespierre Queiroz da Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">Minas Gerais</named-content>
        </addr-line>
        <institution content-type="orgname">Secretaria de Estado da Sa&#250;de de Minas Gerais</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>07</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>1</issue>
      <fpage>e24</fpage>
      <lpage>e26</lpage>
      <history>
        <date date-type="accepted">
          <day>09</day>
          <month>12</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>10</month>
          <year>2009</year>
        </date>
        <date date-type="received">
          <day>08</day>
          <month>07</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Esta reflex&#227;o cr&#237;tica discute os descaminhos do modelo hegem&#244;nico flexineriano da pr&#225;tica m&#233;dica, realizada sob a &#243;tica da paleomedicina, e evid&#234;ncias relevantes oriundas de pesquisas. Se por um lado possu&#237;mos um conhecimento preciso e suficiente sobre a carga de doen&#231;as que afligem a humanidade e seus determinantes, por outro lado a aten&#231;&#227;o volta-se para estrat&#233;gias que n&#227;o causam impacto de forma efetiva em tais doen&#231;as, consumindo um volume maior de recursos destinados &#224; sa&#250;de: doen&#231;as cardiovasculares isqu&#234;micas seguidas pelo diabete melito II. Seus fatores de risco s&#227;o bem conhecidos e comprovadamente control&#225;veis atrav&#233;s de a&#231;&#245;es de promo&#231;&#227;o da sa&#250;de, que constituem uma tecnologia de processo mais custo-efetiva do que a biotecnologia. Entretanto, opta-se por aplicar grande parte dos recursos financeiros na assist&#234;ncia ao indiv&#237;duo j&#225; enfermo em detrimento da promo&#231;&#227;o da sa&#250;de da popula&#231;&#227;o, que prescinde ent&#227;o deste benef&#237;cio, determinando uma iniquidade nas a&#231;&#245;es de sa&#250;de.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Artigo hist&#243;rico</kwd>
        <kwd>doen&#231;as cardiovasculares</kwd>
        <kwd>biotecnologia</kwd>
        <kwd>an&#225;lise custo-benef&#237;cio</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>29</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>PONTO DE VISTA</bold>
    </p>
    <p>Cardiologista - um Prometeu acorrentado</p>
    <p>
      <bold>Robespierre Queiroz da Costa Ribeiro</bold>
    </p>
    <p> Secretaria de Estado de Sa&#250;de de Minas Gerais, Belo Horizonte, MG - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>SUM&#193;RIO</bold>
    </p>
    <p>Esta reflex&#227;o cr&#237;tica discute os descaminhos do modelo hegem&#244;nico <italic>flexineriano</italic> da pr&#225;tica m&#233;dica, realizada sob a &#243;tica da paleomedicina, e evid&#234;ncias relevantes oriundas de pesquisas. Se por um lado possu&#237;mos um conhecimento preciso e suficiente sobre a carga de doen&#231;as que afligem a humanidade e seus determinantes, por outro lado a aten&#231;&#227;o volta-se para estrat&#233;gias que n&#227;o causam impacto de forma efetiva em tais doen&#231;as, consumindo um volume maior de recursos destinados &#224; sa&#250;de: doen&#231;as cardiovasculares isqu&#234;micas seguidas pelo diabete melito II. Seus fatores de risco s&#227;o bem conhecidos e comprovadamente control&#225;veis atrav&#233;s de a&#231;&#245;es de promo&#231;&#227;o da sa&#250;de, que constituem uma tecnologia de processo mais custo-efetiva do que a biotecnologia. Entretanto, opta-se por aplicar grande parte dos recursos financeiros na assist&#234;ncia ao indiv&#237;duo j&#225; enfermo em detrimento da promo&#231;&#227;o da sa&#250;de da popula&#231;&#227;o, que prescinde ent&#227;o deste benef&#237;cio, determinando uma iniquidade nas a&#231;&#245;es de sa&#250;de.</p>
    <p><bold>Palavras-chave:</bold> Artigo hist&#243;rico, doen&#231;as cardiovasculares, biotecnologia, an&#225;lise custo-benef&#237;cio.</p>
    <p>"Nada em Biologia faz sentido, se n&#227;o for </p>
    <p> analisado sob a luz da evolu&#231;&#227;o." </p>
    <p> Theodosius Dobzhansky</p>
    <p>Como na mitologia grega, o cardiologista encarna hoje a figura de Prometeu<xref ref-type="fn" rid="nt01"><sup><italic>1*</italic></sup></xref>. Isso porque, de posse de um conhecimento capaz de reduzir efetivamente a carga de doen&#231;as cardiovasculares (DCVs) que aflige atualmente a popula&#231;&#227;o, atrav&#233;s de medidas de promo&#231;&#227;o da sa&#250;de e preven&#231;&#227;o prim&#225;ria destas doen&#231;as, o cardiologista, acorrentado ao seu <italic>C&#225;ucaso -</italic> representado pelo modelo curativo <italic>hospitaloc&#234;ntrico</italic>, com impacto irris&#243;rio na sa&#250;de da popula&#231;&#227;o -, &#233; ent&#227;o impedido de oferecer uma condi&#231;&#227;o melhor de sa&#250;de cardiovascular &#224; popula&#231;&#227;o. </p>
    <p>As DCVs passam a constituir a maior de todas as endemias a partir da segunda metade do s&#233;culo XX, sendo respons&#225;vel pelo maior n&#250;mero de &#243;bitos no mundo, atualmente em uma escala de um em cada tr&#234;s &#243;bitos e 6 vezes o n&#250;mero de &#243;bitos causados pelo HIV/AIDS<sup>1</sup>. Essa situa&#231;&#227;o dever&#225; manter-se nas pr&#243;ximas d&#233;cadas, em todo o mundo, incluindo os pa&#237;ses em desenvolvimento<sup>2</sup>. Quanto &#224; morbidade, no Brasil as DCVs s&#227;o respons&#225;veis pelos maiores valores de Anos de Vida Perdidos Ajustados por Incapacidade (<italic>Disability Adjusted Life Years - DALYs</italic>)<sup>3</sup>. </p>
    <p>J&#225; se encontram bem determinados os fatores de risco "control&#225;veis", respons&#225;veis por 90% da mais expressiva forma das DCVs, o infarto agudo do mioc&#225;rdio, compreendendo a dislipidemia, diabete melito tipo II (DM-II), tabagismo, hipertens&#227;o arterial sist&#234;mica, excesso de peso com distribui&#231;&#227;o central e ansiedade/depress&#227;o<sup>4</sup>. Tamb&#233;m &#233; conhecido que tr&#234;s fatores de risco - tabagismo, dieta inadequada e baixos n&#237;veis de atividade f&#237;sica - contribuem para o desenvolvimento de 4 doen&#231;as cr&#244;nicas importantes - DCV, DM-II, doen&#231;as pulmonares e v&#225;rios tipos de c&#226;ncer -, respons&#225;veis por mais de 50% das mortes em todo o mundo<sup>5</sup>.</p>
    <p>Os h&#225;bitos de vida considerados adversos &#224; sa&#250;de, surgidos como aquisi&#231;&#227;o conjunta &#224; industrializa&#231;&#227;o e urbaniza&#231;&#227;o de uma sociedade que os importa, modificando antigos h&#225;bitos salutares, trazem consigo um aumento concomitante das taxas de preval&#234;ncia dos FRCVs, dentre eles o excesso de peso<sup>6</sup>.</p>
    <p>O <italic>pool</italic> gen&#233;tico, a partir do qual derivaram os gen&#243;tipos individuais dos seres humanos atuais, mudou muito pouco desde que o <italic>Homo sapiens </italic>espalhou-se pelo planeta h&#225; cerca de 35 mil anos, considerado o &#250;ltimo per&#237;odo de tempo durante o qual o <italic>pool</italic> gen&#233;tico humano coletivo interagiu com as circunst&#226;ncias bioambientais t&#237;picas daquelas para as quais foi originalmente selecionado<sup>7</sup>.</p>
    <p>Por essa &#233;poca pr&#233;-hist&#243;rica, surgiu o denominado <italic>Gen&#243;tipo de Poupan&#231;a</italic> (<italic>Thrifty Genotype</italic>), de vital import&#226;ncia para os nossos ancestrais pr&#233;-hist&#243;ricos, que eram basicamente ca&#231;adores e, como tais, muitas vezes, passavam dias sem conseguir o alimento. Assim, em tempos de abund&#226;ncia, desenvolveram mecanismos que permitiram o armazenamento de energia na forma de gordura, que logo era consumida nas atividades f&#237;sicas di&#225;rias, na busca pela ca&#231;a durante a jornada de preda&#231;&#227;o e, mais ainda, durante os frequentes per&#237;odos de car&#234;ncia alimentar.</p>
    <p>No mundo atual, esse gen&#243;tipo, antes de muito proveito, torna-se desvantajoso agora que a comida &#233; abundante, favorecendo uma elevada preval&#234;ncia de excesso de peso e suas comorbidades associadas (DCVs e DM-II), denominadas ent&#227;o de S&#237;ndromes de Disfun&#231;&#227;o da Homeostase Gen&#233;tica. Essa incompatibilidade entre a nossa formata&#231;&#227;o original e as circunst&#226;ncias ambientais atuais, determinando uma disson&#226;ncia entre os genes da "idade da pedra" e o ambiente da "idade espacial", leva a uma ruptura dos complexos sistemas homeost&#225;ticos ancestrais<sup>8,9</sup>.</p>
    <p>As r&#225;pidas altera&#231;&#245;es culturais que ocorreram durante os &#250;ltimos 10 mil anos n&#227;o foram acompanhadas por quaisquer adapta&#231;&#245;es gen&#233;ticas poss&#237;veis, especificamente porque muitas destas altera&#231;&#245;es culturais ocorreram ap&#243;s a Revolu&#231;&#227;o Industrial, h&#225; apenas 200 anos<sup>7,8</sup>.</p>
    <p>Da&#237; surge a proposta da denominada <italic>preven&#231;&#227;o prim&#225;ria baseada na evolu&#231;&#227;o</italic> (<italic>evolution-based prevention</italic>) ou <italic>promo&#231;&#227;o da sa&#250;de de base evolutiva</italic> (<italic>evolutionary-based health promotion</italic>), ou seja, uma abordagem evolutiva para a medicina preventiva que, n&#227;o necessariamente, op&#245;e-se ao crescimento econ&#244;mico moderno e, certamente, n&#227;o se posiciona contra as conquistas da medicina e da sa&#250;de p&#250;blica<sup>8</sup>.</p>
    <p>Conhecemos a magnitude do problema atrav&#233;s das taxas de morbimortalidade da doen&#231;a (DCVs); j&#225; temos bem definidos os seus principais fatores e indicadores de risco; j&#225; se encontram dispon&#237;veis estrat&#233;gias efetivas para o seu enfrentamento e experi&#234;ncias exitosas; entretanto, paradoxalmente, permanecemos priorizando as a&#231;&#245;es curativas que contribuem muito pouco para a redu&#231;&#227;o dos fatores de risco cardiovasculares.</p>
    <p>Continuamos, ent&#227;o, presos ao <italic>C&#225;ucaso</italic> pelos grilh&#245;es de um modelo perverso que prioriza o lucro e as a&#231;&#245;es que movimentam o capital na roda da <italic>ind&#250;stria da doen&#231;a</italic>. Os escassos recursos destinados &#224; sa&#250;de s&#227;o gastos em sua maioria com as tecnologias denominadas <italic>intensivas</italic> (medicamentos, equipamentos, exames diagn&#243;sticos e procedimentos de alta complexidade), consideradas de alto custo e que ir&#227;o beneficiar uma pequena parcela da popula&#231;&#227;o, deixando, por outro lado, uma grande parcela, que se beneficiaria de tecnologias de promo&#231;&#227;o da sa&#250;de e preven&#231;&#227;o prim&#225;ria consideradas mais efetivas e de menor custo, consequentemente prejudicada por este deslocamento de recursos t&#227;o apropriadamente denominado <italic>custo de oportunidade</italic>.</p>
    <p>Tem sido exaustivamente demonstrado que as estrat&#233;gias de preven&#231;&#227;o primordial (ou promo&#231;&#227;o da sa&#250;de)/preven&#231;&#227;o prim&#225;ria apresentam uma rela&#231;&#227;o <italic>custo-efetividade incremental</italic> mais favor&#225;vel que aquelas denominadas <italic>high-end care for advanced disease</italic>. Em rela&#231;&#227;o &#224;s DCVs isqu&#234;micas, &#233; estimado, nos pa&#237;ses em desenvolvimento, um custo em torno de $ 25,00 a $ 4.000,00 d&#243;lares para cada ano de vida com incapacidade (DALY) evitado atrav&#233;s de implementa&#231;&#227;o de estrat&#233;gias de preven&#231;&#227;o prim&#225;ria (promo&#231;&#227;o da sa&#250;de). J&#225; o custo de um tratamento com cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica associada com betabloqueador, aspirina, inibidores da ECA e estatina (lovastatina) sobe para $ 24.000,00 a $ 72.000,00 d&#243;lares por cada DALY evitado<sup>9</sup>.</p>
    <p>Os recursos gastos com a preven&#231;&#227;o das DCVs n&#227;o deveriam ser vistos como gasto n&#227;o produtivo, mas sim como um investimento verdadeiramente produtivo, visto que a maioria das pessoas que morrem em decorr&#234;ncia destas doen&#231;as perde a vida justamente na faixa et&#225;ria mais produtiva.</p>
    <p>Preso &#224; montanha do lucro, encontra-se assim o m&#233;dico, v&#237;tima de uma <italic>farmacologiza&#231;&#227;o</italic> e <italic>tecnologiliza&#231;&#227;o</italic> da sua rela&#231;&#227;o com o paciente, consequ&#234;ncia de uma sociedade baseada no lucro, que vilipendia a medicina, tornando-a muitas vezes um neg&#243;cio disfar&#231;ado de ci&#234;ncia e humanismo.</p>
    <p>Urge ent&#227;o que se implemente um amplo programa de sa&#250;de p&#250;blica, divulgando os conceitos sobre os fatores de risco, bem como identificando e tratando precocemente os indiv&#237;duos expostos ou com risco cardiovascular al&#233;m do ideal. Devemos lembrar que, nessa &#250;ltima d&#233;cada, na literatura m&#233;dica, tem se acumulado diversas evid&#234;ncias de que tal abordagem seria mais efetiva quanto mais precoce for iniciada, isto &#233;, junto &#224;s crian&#231;as e aos adolescentes, que respondem melhor e mais rapidamente aos programas de preven&#231;&#227;o de doen&#231;as, particularmente &#224; promo&#231;&#227;o da sa&#250;de, al&#233;m de serem &#243;timos multiplicadores entre a popula&#231;&#227;o adulta no &#226;mbito do lar.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Robespierre Queiroz da Costa Ribeiro </p>
        <p> Al. Guilherme Henrique Daniel, 94/302 - Serra </p>
        <p> 30220-200 - Belo Horizonte, MG - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="rqueiroz@cardiol.br">rqueiroz@cardiol.br</email>, </p>
        <p>
          <email xlink:href="dr.robespierre@gmail.com">dr.robespierre@gmail.com</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 08/07/09; revisado recebido em 06/10/09; aceito em 09/12/09.</p>
    <p>
      <fn id="nt01">
        <label>1*</label>
        <p> Prometeu foi um tit&#227; que criou os homens e roubou o fogo dos deuses para presente&#225;-lo &#224;s suas cria&#231;&#245;es. Como castigo, foi acorrentado no monte C&#225;ucaso, onde todos os dias uma &#225;guia, ou um corvo, dilaceraria o seu f&#237;gado, que, por ser Prometeu imortal, regenerava-se. Prometeu representa a vontade humana por conhecimento, sua captura do fogo &#233; a aud&#225;cia humana pela busca de conhecimento e do desejo de compartilh&#225;-lo.</p>
      </fn>
    </p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. World Heart Federation (WHF). World Heart Day focus on obesity. [Acesso em 2002 nov 10]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.worldheart.org">http://www.worldheart.org</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>World Heart Day focus on obesity</source>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Murray CJL, Lopez AD. The global burden of    disease: a comprehensive assessment of mortality and disability from diseases,    injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard University    Press; 1996.</mixed-citation>
        <element-citation publication-type="book">
          <source>The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020</source>
          <date>
            <year>1996</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>CJL</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Schramm JM, Valente JG, Leite IC, Campos MR,    Gadelha AMJ, Portela MC, et al. Perfil epidemiol&#243;gico segundo os resultados    do estudo de carga de doen&#231;a no Brasil. Minist&#233;rio da Sa&#250;de.    In: Sa&#250;de no Brasil - contribui&#231;&#245;es para a agenda nacional    de prioridades de pesquisa. Bras&#237;lia; 2004. (S&#233;rie B. Textos B&#225;sicos    de Sa&#250;de).</mixed-citation>
        <element-citation publication-type="book">
          <source>Sa&#250;de no Brasil: contribui&#231;&#245;es para a agenda nacional de prioridades de pesquisa</source>
          <date>
            <year>2004</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Schramm</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Valente</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Leite</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>AMJ</given-names>
            </name>
            <name>
              <surname>Portela</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Yusuf S, Hawken S, &#212;unpuu S, Dans T,    Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated    with myocardial infarction in 52 countries (The INTERHEART study): case-control    study. Lancet. 2004; 364 (9438): 937-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-control study</article-title>
          <source>Lancet</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>937</fpage>
          <lpage>52</lpage>
          <issue>9438</issue>
          <volume>364</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawken</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>&#212;unpuu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dans</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Avezum</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lanas</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. The Oxford Health Alliance - 3FOUR50. [Acesso em 2007 set 16]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://3four50.com">http://3four50.com</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>The Oxford Health Alliance: 3FOUR50</source>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular    disease in developing countries. Circulation. 1998; 97: 596-601.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Emerging epidemic of cardiovascular disease in developing countries</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>596</fpage>
          <lpage>601</lpage>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Eaton SB, Konner M, Shostak M. Stone agers    in the fast lane: chronic degenerative diseases in evolutionary perspective.    Am J Med. 1988; 84: 739-49.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective</article-title>
          <source>Am J Med</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>739</fpage>
          <lpage>49</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Eaton</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Konner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shostak</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Abuissa H, O'Keefe JH, Cordain L. Realigning    our 21st century diet and lifestyle with our hunter-gatherer genetic identity.    Directions Psych. 2005; 25: SR1-SR10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Realigning our 21st century diet and lifestyle with our hunter-gatherer genetic identity</article-title>
          <source>Directions Psych</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>SR1</fpage>
          <lpage>SR10</lpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abuissa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>O'Keefe JH</surname>
            </name>
            <name>
              <surname>Cordain</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Gaziano TA. Reducing the growing burden of    cardiovascular disease in the developing world. Health Affairs. 2007; 26 (1):    13-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reducing the growing burden of cardiovascular disease in the developing world</article-title>
          <source>Health Affairs</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>13</fpage>
          <lpage>24</lpage>
          <issue>1</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gaziano</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Point of View</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">The cardiologist: a chained Prometheus</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>This critical review discusses the deviations from the Flexnerian hegemonic model of medical practice, carried out under the point of view of paleomedicine and relevant evidence from research. If we, on the one hand, have the required and sufficient knowledge on the burden of diseases that afflict mankind and its determinant factors, on the other hand the attention turns to strategies that do not have an effective impact on such diseases, consuming a larger portion of resources directed to healthcare: ischemic cardiovascular diseases, followed by type 2 diabetes mellitus. Their risk factors are well-known and have been shown to be controllable through health promotion actions, which constitute a process technology that is more cost-effective than biotechnology. However, we choose to apply large part of the financial resources on the care of the affected individual to the detriment of health promotion in the general population, who goes without this benefit, which characterizes an injustice in terms of healthcare actions.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Historical article</kwd>
        <kwd>cardiovascular diseases</kwd>
        <kwd>biotechnology</kwd>
        <kwd>cost-benefit analysis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>POINT OF VIEW</bold>
      </p>
      <p><undefined id="tx-body2"/>The cardiologist - a chained Prometheus</p>
      <p>
        <bold>Robespierre Queiroz da Costa Ribeiro</bold>
      </p>
      <p> Secretaria de Estado de Sa&#250;de de Minas Gerais, Belo Horizonte, MG - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>This critical review discusses the deviations from the Flexnerian hegemonic model of medical practice, carried out under the point of view of paleomedicine and relevant evidence from research. If we, on the one hand, have the required and sufficient knowledge on the burden of diseases that afflict mankind and its determinant factors, on the other hand the attention turns to strategies that do not have an effective impact on such diseases, consuming a larger portion of resources directed to healthcare: ischemic cardiovascular diseases, followed by type 2 diabetes mellitus. Their risk factors are well-known and have been shown to be controllable through health promotion actions, which constitute a process technology that is more cost-effective than biotechnology. However, we choose to apply large part of the financial resources on the care of the affected individual to the detriment of health promotion in the general population, who goes without this benefit, which characterizes an injustice in terms of healthcare actions. </p>
      <p><bold>Key words:</bold> Historical article; cardiovascular diseases; biotechnology; cost-benefit analysis.</p>
      <p>"Nothing in Biology makes sense, </p>
      <p> except in the Light of Evolution."</p>
      <p> Theodosius Dobzhansky</p>
      <p>As in the Greek mythology, in our time, the cardiologist personifies the mythical figure of Prometheus<fn id="tx01-body2"><label><sup><italic>1*</italic></sup></label><p>. That, because having the necessary knowledge to effectively reduce the burden of cardiovascular diseases (CVD) that currently afflicts the population through health-promotion measures and primary prevention of diseases, cardiologists, chained to their </p><p><italic>Caucasus</italic> - represented by the hospital-centric curative model, with a negligible impact on the population health - is thus prevented from offering a better cardiovascular health condition to the population. </p></fn></p>
      <p>CVD started to constitute the most important endemic diseases from the second half of the XX century on, accounting for the largest number of deaths worldwide, currently at a scale of one in three deaths and 6 times the number of deaths caused by HIV/AIDS<sup>1</sup>. This situation tends to remain unaltered in the following decades throughout the world, including in developing countries<sup>2</sup>. As for the morbidity, in Brazil CVD are responsible for the highest values of Disability Adjusted Life Years (DALY)<sup>3</sup>. </p>
      <p>The "controllable" risk factors have been well determined, which account for 90% of the most significant form of CVD, the acute myocardial infarction (AMI), comprehending dyslipidemia, type 2 diabetes mellitus (DM-II), smoking, systemic arterial hypertension, excess weight with central distribution and anxiety/depression<sup>4</sup>. It is also well-known that three risk factors - smoking, inadequate diet and low levels of physical activity - contribute to the development of 4 important chronic diseases - CVD, DM-II, pulmonary diseases and several types of cancer - responsible for more than 50% of the deaths worldwide<sup>5</sup>.</p>
      <p>The life habits considered hazardous to health, which appeared as an aftermath of industrialization and urbanization of a society that imported them, modifying old healthy habits, bring a concomitant increase to the prevalence rate of CVD risk factors, among them excess weight<sup>6</sup>. </p>
      <p>The genetic pool, from which the individual genotypes of the modern human beings originated, changed very little since the <italic>Homo sapiens</italic> populated the planet, approximately 35,000 years ago, considered the last period of time during which the collective human genetic pool interacted with the typical bioenvironmental circumstances of those for which it was originally selected<sup>7</sup>. </p>
      <p>By this pre-historical time, the "Thrifty Genotype" appeared, which was of vital importance for our pre-historical ancestors, who were basically hunters, and thus, very often went days without food. Hence, during times of abundance, they developed mechanisms that allowed the storage of energy as fat, which was consumed during the daily physical activities during hunting for the procurement of food and, even more significantly, during the frequent periods of food scarcity. </p>
      <p>In the modern world, this genotype, which was previously very useful for the survival of the species, became disadvantageous, favoring a high prevalence of excess weight and its associated comorbidities (CVD and DM-II), then called "Genetic Homeostasis Dysfunction Syndromes". This incompatibility between our original formatting and the current environmental circumstances, which determines a conflict between the "Stone-age genes" and the "Space-age environment", leads to a rupture of complex ancestral homeostatic systems<sup>98,9,10</sup>.</p>
      <p>The rapid cultural alterations that occurred during the last 10,000 years were not accompanied by any possible genetic adaptations, specifically because many of these cultural alterations occurred after the Industrial Revolution, barely 200 years ago<sup>7,8</sup>.</p>
      <p>Hence came the proposal of the so-called ""evolution-based prevention or ""evolutionary-based health promotion, that is, an evolutionary approach for prevention Medicine which does not necessarily oppose the modern economic growth model and certainly does not go against the conquests of Medicine and public health<sup>8</sup>.</p>
      <p>We are aware of the magnitude of the problem through the rates of morbimortality of the disease (CVD); we have already defined its main risk factors and indicators; effective strategies to fight the disease and successful experiences are available; however, paradoxically, we continue to prioritize the curative actions that contribute very little to the decrease the cardiovascular risk factors.</p>
      <p>We remain, then, chained to the <italic>Caucasus</italic> by the fetters of a perverse model that prioritizes profit and the actions that keeps the assets flowing in the wheel of the <italic>industry of disease</italic>. The scarce resources destined to healthcare are spent mostly with the so-called "intensive" technologies (medications, equipment, diagnostic examinations and high-complex procedures), considered to be high-cost and that will benefit a small percentage of the population, to the detriment of a large percentage that would benefit from health-promotion and primary prevention technologies, considered to be more effective and lower-cost, consequently impaired by this deviation of resources, which is so appropriately called "opportunity cost".</p>
      <p>It has been extensively demonstrated that the elementary prevention (or health promotion)/primary prevention strategies have an incremental more favorable cost-effectiveness association than those called high-end care for advanced disease. Regarding the ischemic CVD, in developing countries, a cost of approximately $ 25.00 to $ 4,000.00 dollars is estimated for each disability adjusted life year prevented (DALY) through the implementation of primary prevention strategies (health promotion). As for the cost of a treatment that includes myocardial revascularization associated with beta-blocker, aspirin, ACE inhibitors and statins (lovastatin), the cost increases to $ 24,000.00 up to $ 72,000.00 dollars for each DALY prevented<sup>9</sup>.</p>
      <p>The resources spent with the prevention of CVD should not be seen as non-productive expenses, but as a truly productive investment, considering that most people who die due to these diseases do so exactly at the most productive age range.</p>
      <p>Thus, physicians are chained to the mountain of profit, the victims of a <italic>pharmacologization</italic> and <italic>technologization</italic> of their relationship with their patients, a consequence a profit-based society that vilifies Medicine, very often turning it into a business masquerading as science and humanism.</p>
      <p>It is therefore necessary to implement a broad public health program, disseminating the concepts on risk factors, as well as identifying and treating, as early as possible, individuals exposed to or who present cardiovascular risks that are higher than the ideal situation.</p>
      <p>One must recall that in the last decade, the medical literature has accumulated evidence that the earlier such approach was started, the more effective it would be, that is, starting it with children and adolescents, who respond better and more quickly to disease prevention programs, particularly to health promotion ones, in addition to being great multipliers among the adult population inside the home.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">El cardi&#243;logo: un prometeo encadenado</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>Esta reflexi&#243;n cr&#237;tica discute los extrav&#237;os del modelo hegem&#243;nico flexineriano de la pr&#225;ctica m&#233;dica, realizada bajo la &#243;ptica de la paleomedicina, y evidencias relevantes oriundas de investigaciones. Si por un lado poseemos un conocimiento preciso y suficiente sobre la carga de enfermedades que afligen a la humanidad y sus determinantes, por otro lado la atenci&#243;n se vuelca hacia estrategias que no causan impacto de forma efectiva en tales enfermedades, consumiendo un volumen mayor de recursos destinados a la salud: enfermedades cardiovasculares isqu&#233;micas seguidas por diabetes mellitus II. Sus factores de riesgo son bien conocidos y comprobadamente controlables a trav&#233;s de acciones de promoci&#243;n de la salud, que constituyen una tecnolog&#237;a de proceso m&#225;s costo-efectiva que la biotecnolog&#237;a. Entre tanto, se opta por aplicar gran parte de los recursos financieros en la asistencia al individuo ya enfermo en detrimento de la promoci&#243;n de la salud de la poblaci&#243;n, que prescinde entonces de este beneficio, determinando una iniquidad en las acciones de salud.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Art&#237;culo hist&#243;rico</kwd>
        <kwd>enfermedades cardiovasculares</kwd>
        <kwd>biotecnolog&#237;a</kwd>
        <kwd>an&#225;lisis costo-beneficio</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>PUNTO DE VISTA</bold>
      </p>
      <p>El cardi&#243;logo - un prometeo encadenado</p>
      <p>
        <bold>Robespierre Queiroz da Costa Ribeiro</bold>
      </p>
      <p>Secretaria de Estado de Sa&#250;de de Minas Gerais, Belo Horizonte, MG - Brasil</p>
      <p>
        <xref ref-type="corresp" rid="add1-body3">Correspondencia</xref>
      </p>
      <p>
        <bold>Sumario</bold>
      </p>
      <p>Esta reflexi&#243;n cr&#237;tica discute los extrav&#237;os del modelo hegem&#243;nico <italic>flexineriano</italic> de la pr&#225;ctica m&#233;dica, realizada bajo la &#243;ptica de la paleomedicina, y evidencias relevantes oriundas de investigaciones. Si por un lado poseemos un conocimiento preciso y suficiente sobre la carga de enfermedades que afligen a la humanidad y sus determinantes, por otro lado la atenci&#243;n se vuelca hacia estrategias que no causan impacto de forma efectiva en tales enfermedades, consumiendo un volumen mayor de recursos destinados a la salud: enfermedades cardiovasculares isqu&#233;micas seguidas por diabetes mellitus II. Sus factores de riesgo son bien conocidos y comprobadamente controlables a trav&#233;s de acciones de promoci&#243;n de la salud, que constituyen una tecnolog&#237;a de proceso m&#225;s costo-efectiva que la biotecnolog&#237;a. Entre tanto, se opta por aplicar gran parte de los recursos financieros en la asistencia al individuo ya enfermo en detrimento de la promoci&#243;n de la salud de la poblaci&#243;n, que prescinde entonces de este beneficio, determinando una iniquidad en las acciones de salud.</p>
      <p><bold>Palabras clave:</bold> Art&#237;culo hist&#243;rico, enfermedades cardiovasculares, biotecnolog&#237;a, an&#225;lisis costo-beneficio.</p>
      <p>"Nada en Biolog&#237;a tiene sentido, si no es</p>
      <p> analizado bajo la luz de la evoluci&#243;n."</p>
      <p> Theodosius Dobzhansky</p>
      <p>Como en la mitologia griega, el cardi&#243;logo encarna hoy la figura de <italic>Prometeo</italic><xref ref-type="fn" rid="fn1b-body3"><sup>1*</sup></xref>. Eso porque, en posesi&#243;n de un conocimiento capaz de reducir efectivamente la carga de enfermedades cardiovasculares (ECVs) que aflige actualmente a la poblaci&#243;n, a trav&#233;s de medidas de promoci&#243;n de la salud y prevenci&#243;n primaria de estas enfermedades, el cardi&#243;logo, encadenado a su <italic>C&#225;ucaso -</italic> representado por el modelo curativo <italic>hospitaloc&#233;ntrico</italic>, con impacto irrisorio en la salud de la populaci&#243;n -, est&#225; entonces impedido de ofrecer una condici&#243;n mejor de salud cardiovascular a la populaci&#243;n. </p>
      <p>Las ECVs pasan a constituir la mayor de todas las endemias a partir de la segunda mitad del siglo XX, siendo responsables por el mayor n&#250;mero de &#243;bitos en el mundo, actualmente en una escala de uno en cada tres &#243;bitos y 6 veces el n&#250;mero de &#243;bitos causados por el HIV/AIDS<sup>1</sup>. Esa situaci&#243;n deber&#225; mantenerse en las pr&#243;ximas d&#233;cadas, en todo el mundo, incluyendo los pa&#237;ses en desarrollo<sup>2</sup>. En cuanto a la morbilidad, en el Brasil las ECVs son responsables por los mayores valores de A&#241;os de Vida Perdidos Ajustados por Incapacidad (<italic>Disability Adjusted Life Years - DALYs</italic>)<sup>3</sup>.</p>
      <p>Ya se encuentran bien determinados los factores de riesgo "controlables", responsables por 90% de la m&#225;s expresiva forma de las ECVs, el infarto agudo de miocardio, comprendiendo la dislipidemia, diabetes melittus tipo II (DM-II), tabaquismo, hipertensi&#243;n arterial sist&#233;mica, exceso de peso con distribuci&#243;n central y ansiedad/depresi&#243;n<sup>4</sup>. Tambi&#233;n es conocido que tres factores de riesgo - tabaquismo, dieta inadecuada y bajos niveles de actividad f&#237;sica - contribuyen al desarrollo de 4 enfermedades cr&#243;nicas importantes - ECV, DM-II, enfermedades pulmonares y varios tipos de c&#225;ncer -, responsables por m&#225;s de 50% de las muertes en todo el mundo<sup>5</sup>.</p>
      <p>Los h&#225;bitos de vida considerados adversos a la salud, surgidos como adquisici&#243;n conjunta a la industrializaci&#243;n y urbanizaci&#243;n de una sociedad que los importa, modificando antiguos h&#225;bitos de salud, traen consigo un aumento concomitante de las tasas de prevalencia de los FRCVs, entre ellos el exceso de peso<sup>6</sup>.</p>
      <p>EL <italic>pool</italic> gen&#233;tico, a partir del cual derivaron los genotipos individuales de los seres humanos actuales, cambi&#243; muy poco desde que el <italic>Homo sapiens </italic>se extendi&#243; por el planeta hace cerca de 35 mil a&#241;os, considerado el &#250;ltimo per&#237;odo de tiempo durante el cual el <italic>pool</italic> gen&#233;tico humano colectivo interactu&#243; con las circunstancias bioambientales t&#237;picas de aquellas para las cuales fue originalmente seleccionado<sup>7</sup>.</p>
      <p>Por esa &#233;poca prehist&#243;rica, surgi&#243; el denominado <italic>Genotipo de Ahorro</italic> (<italic>Thrifty Genotype</italic>), de vital importancia para nuestros ancestros prehist&#243;ricos, que eran b&#225;sicamente cazadores y, como tales, muchas veces, pasaban d&#237;as sin conseguir alimento. As&#237;, en tiempos de abundancia, desarrollaron mecanismos que permitieron el almacenamiento de energ&#237;a en forma de grasa, que despu&#233;s era consumida en las actividades f&#237;sicas diarias, en la b&#250;squeda de la caza durante la jornada predatoria y, m&#225;s a&#250;n, durante los frecuentes per&#237;odos de carencia alimenticia.</p>
      <p>En el mundo actual, ese genotipo, antes de mucho provecho, se vuelve desventajoso ahora que la comida es abundante, favoreciendo una elevada prevalencia de exceso de peso y sus comorbilidades asociadas (ECVs y DM-II), denominadas entonces de S&#237;ndromes de Disfunci&#243;n de la Homeostasis Gen&#233;tica. Esa incompatibilidad entre nuestro modelo original y las circunstancias ambientales actuales, determinando una disonancia entre los genes de la "edad de piedra" y el ambiente de la "edad espacial", lleva a una ruptura de los complejos sistemas homeost&#225;ticos ancestraisales<sup>8,9</sup>.</p>
      <p>Las r&#225;pidas alteraciones culturales que ocurrieron durante los &#250;ltimos 10 mil a&#241;os no fueron acompa&#241;adas por algunas adaptaciones gen&#233;ticas posibles, espec&#237;ficamente porque muchas de estas alteraciones culturales ocurrieron despu&#233;s de la Revoluci&#243;n Industrial, hace apenas 200 a&#241;os<sup>7,8</sup>.</p>
      <p>De ah&#237; surge la propuesta de la denominada <italic>prevenci&#243;n primaria basada en la evoluci&#243;n</italic> (<italic>evolution-based prevention</italic>) o <italic>promoci&#243;n de la salud de base evolutiva</italic> (<italic>evolutionary-based health promotion</italic>), o sea, un abordaje evolutivo para la medicina preventiva que, no necesariamente, se opone al crecimiento econ&#243;mico moderno y, ciertamente, no se posiciona contra las conquistas de la medicina y de la salud p&#250;blica<sup>8</sup>.</p>
      <p>Conocemos la magnitud del problema a trav&#233;s de las tasas de morbimortalidad de la enfermedad (ECVs); ya tenemos bien definidos sus principales factores e indicadores de riesgo; ya se encuentran disponibles estrategias efectivas para su enfrentamiento y experiencias exitosas; entretanto, parad&#243;jicamente, permanecemos priorizando las acciones curativas que contribuyen muy poco a la reducci&#243;n de los factores de riesgo cardiovasculares. </p>
      <p>Continuamos, entonces, presos al <italic>C&#225;ucaso</italic> por los grilletes de un modelo perverso que prioriza el lucro y las acciones que mueven el capital en la rueda de la <italic>industria de la enfermedad</italic>. Los escasos recursos destinados a la salud son gastados en su mayor&#237;a con las tecnolog&#237;as denominadas <italic>intensivas</italic> (medicamentos, equipamientos, ex&#225;menes diagn&#243;sticos y procedimientos de alta complejidad), consideradas de alto costo y que ir&#225;n a beneficiar una peque&#241;a parte de la poblaci&#243;n, dejando, por otro lado, una gran parte, que se beneficiaria de tecnolog&#237;as de promoci&#243;n de la salud y prevenci&#243;n primaria consideradas m&#225;s efectivas y de menor costo, consecuentemente perjudicada por este desplazamiento de recursos tan apropiadamente denominado <italic>costo de oportunidad</italic>.</p>
      <p>Ha sido exhaustivamente demostrado que las estrategias de prevenci&#243;n primordial (o promoci&#243;n de la salud)/prevenci&#243;n primaria presentan una relaci&#243;n <italic>costo-efectividad incremental</italic> m&#225;s favorable que aquellas denominadas <italic>high-end care for advanced disease</italic>. En relaci&#243;n a las ECVs isqu&#233;micas, es estimado, en los pa&#237;ses en desarrollo, un costo alrededor de $25,00 a $4.000,00 d&#243;lares para cada a&#241;o de vida con incapacidad (DALY) evitado a trav&#233;s de implementaci&#243;n de estrategias de prevenci&#243;n primaria (promoci&#243;n de la salud). Ya el costo de un tratamiento con cirug&#237;a de revascularizaci&#243;n mioc&#225;rdica asociada a betabloqueante, aspirina, inhibidores de la ECA y estatina (lovastatina) sube de $24.000,00 a $72.000,00 d&#243;lares por cada DALY evitado<sup>9</sup>.</p>
      <p>Los recursos gastados en la prevenci&#243;n de las ECVs no deber&#237;an ser vistos como gasto no productivo, sino s&#237; como una inversi&#243;n verdaderamente productiva, visto que la mayor&#237;a de las personas que mueren en consecuencia de estas enfermedades pierde la vida justamente en la franja etaria m&#225;s productiva.</p>
      <p>Preso a la monta&#241;a del lucro, se encuentra as&#237; el m&#233;dico, v&#237;ctima de una <italic>farmacologizaci&#243;n</italic> y <italic>tecnologilizaci&#243;n</italic> de su relaci&#243;n con el paciente, consecuencia de una sociedad basada en el lucro, que vilipendia la medicina, volvi&#233;ndola muchas veces un negocio disfrazado de ciencia y humanismo.</p>
      <p>Urge entonces que se implemente un amplio programa de salud p&#250;blica, divulgando los conceptos sobre los factores de riesgo, as&#237; como identificando y tratando precozmente a los individuos expuestos o con riesgo cardiovascular m&#225;s all&#225; de lo ideal. Debemos recordar que, en esta &#250;ltima d&#233;cada, en la literatura m&#233;dica, se han acumulado diversas evidencias de que tal abordaje ser&#237;a m&#225;s efectiva cuanto m&#225;s precoz sea iniciada, esto es, junto a los ni&#241;os y a los adolescentes, que responden mejor y m&#225;s r&#225;pidamente a los programas de prevenci&#243;n de enfermedades, particularmente a la promoci&#243;n de la salud, adem&#225;s de ser &#243;ptimos multiplicadores entre la poblaci&#243;n adulta en el &#225;mbito del hogar.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>EL presente estudio no tuvo fuentes de financiamiento externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de post-grado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
      <p>1. World Heart Federation (WHF). World Heart Day focus on obesity. [Acesso em 2002 nov 10]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.worldheart.org">http://www.worldheart.org</ext-link>.</p>
      <p>2. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard University Press; 1996.</p>
      <p>3. Schramm JM, Valente JG, Leite IC, Campos MR, Gadelha AMJ, Portela MC, et al. Perfil epidemiol&#243;gico segundo os resultados do estudo de carga de doen&#231;a no Brasil. Minist&#233;rio da Sa&#250;de. In: Sa&#250;de no Brasil - contribui&#231;&#245;es para a agenda nacional de prioridades de pesquisa. Bras&#237;lia; 2004. (S&#233;rie B. Textos B&#225;sicos de Sa&#250;de).</p>
      <p>4. Yusuf S, Hawken S, &#212;unpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-control study. Lancet. 2004; 364 (9438): 937-52. </p>
      <p>5. The Oxford Health Alliance - 3FOUR50. [Acesso em 2007 set 16]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://3four50.com">http://3four50.com</ext-link>.</p>
      <p>6. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998; 97: 596-601.</p>
      <p>7. Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am J Med. 1988; 84: 739-49. </p>
      <p>8. Abuissa H, O'Keefe JH, Cordain L. Realigning our 21st century diet and lifestyle with our hunter-gatherer genetic identity. Directions Psych. 2005; 25: SR1-SR10.</p>
      <p>9. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Affairs. 2007; 26 (1): 13-24.</p>
      <p>
        <fn id="add1-body3" fn-type="corresp">
          <label>
            <bold>Correspondencia:</bold>
          </label>
          <p> Robespierre Queiroz da Costa Ribeiro Al. Guilherme Henrique Daniel</p>
          <p> 94/302 - Serra - 30220-200 - Belo Horizonte, MG - Brasil</p>
          <p> E-mail: </p>
          <p><email xlink:href="rqueiroz@cardiol.br">rqueiroz@cardiol.br</email>, </p>
          <p>
            <email xlink:href="dr.robespierre@gmail.com">dr.robespierre@gmail.com</email>
          </p>
        </fn>
      </p>
      <p>Art&#237;culo recibido el 08/07/09; revisado recibido el 06/10/09; aceptado el 09/12/09.</p>
      <p>
        <fn id="fn1b-body3">
          <label>1*</label>
          <p> Prometeu foifue umn tit&#225;n&#227; que cre&#243;iou a oslos hombresens ey roub&#243;ou elo fueogo de los dioseseuses para darlopresente&#225;-lo a&#224;s suas creacionesia&#231;&#245;es. Como castigo, foifue encadenadoacorrentado en elo monte C&#225;ucaso, donde todos oslos d&#237;ias unma &#225;guila, ou unm couervo, dilacerari&#237;a o seu fh&#237;gado, que, por ser Prometeuo inmortal, se regenerabva-se. Prometeuo representa la voluntadntade humana depor conohecimiento, sua captura delo fouego es&#233; la auda&#225;cia humana enpela la b&#250;squeda busca de conheocimiento ey delo desejo de compartirlh&#225;-lo.</p>
        </fn>
      </p>
    </body>
  </sub-article>
</article>
